The industry-focused Neuromuscular Drug Development Summit helps to overcome the challenges preventing neuromuscular drug developers bringing truly transformative therapeutics to market.
With an emphasis on ALS, SMA, DMD and other rare diseases, 21 expert speakers from the likes of Biogen, Audentes and PTC Therapeutics shared their insights in 2019. Across 3 packed days, this comprehensive learning and networking forum enabled attendees to:
- Form connections for future partnerships by network with the other leading minds in neuromuscular drug development
- Evaluate the success in the clinical landscape to determine where improvement is needed
- Discuss the translational challenges hindering drug developers working on different neuromuscular approaches and develop strategies to improve translation into the clinic
- Establish your work in the field and share your research with your peers at the Poster Session
Join 60+ neuromuscular stakeholders in 2020 to exchange novel ideas, gather lessons learned and establish new collaborations.
Don’t miss your opportunity to be part of the force accelerating change in the wider NMD landscape.
"The event allowed great access to senior people and provided opportunities to collaborate and develop opportunities for further interaction. The speakers provided excellent insight into the state of play in the research areas covered and what still needs to be done. Very worthwhile."
Steven Arnott, Chief Executive Officer, Perron Institute
"Excellent networking and learning opportunity for pharma scientists."
Matthew Kennedy, Director, Merck
"Excellent conference with a very good and diverse set of speakers and topics."
Jim Cassella, Chief Development Officer, Concert Pharmaceuticals